Characteristics and outcome of 11 patients with polyarteritis nodosa treated with tocilizumab
| No | Age (years) | Sex | Disease duration (months) | Treatments before TCZ | CRP (mg/dL) | The reason for TCZ | Dose/frequency | Concomitant treatment | Observation (months) | PSL at last visit |
| 1 | 11 | F | 43 | GC, AZA, MMF, TAC, CyA, IvIg, ETN, IFX, ADA | Elevated | R | 8 mg/kg IV every 2 weeks | PSL, MMF | 7 | Off |
| 2 | 23 | M | 38 | GC, CYC, MTX, RTX, ANA, IvIg | 29.1 | R | 8 mg/kg IV every 4 weeks | PSL 80 mg/day | 37 | 4 mg/day |
| 3 | 24 | M | NA | GC, CYC, IvIg | 29.8 | R | 8 mg/kg IV every 4 weeks | mPSL 250 mg IV | 11 | 5 mg/day |
| 4 | 63 | F | NA | GC | 17.4 | P | 162 mg SC every week | PSL 50 mg/day | 6 | 5 mg/day |
| 5 | 70 | F | NA | GC, MTX | 9.3 | R | 8 mg/kg IV every 4 weeks | mPSL 500 mg IV | 13 | 5 mg/day |
| 6 | 67 | M | 6 | GC, CYC | 2.03 | R | 162 mg SC every week | PSL 16 mg/day, MTX | 15 | 4 mg/day |
| 7 | 39 | F | 120 | GC, CYC, MTX, MMF, IFX | 5.9–12.6 | R | 8 mg/kg IV every 4 weeks | PSL 50 mg/day | 12 | 5 mg/day |
| 8 | 52 | F | 96 | GC, CYC, MTX, AZA, dapsone | Not mentioned | R | 8 mg/kg IV every 4 weeks | PSL 35 mg/day | 12 | 5 mg/day |
| 9 | 35 | M | 3 | GC, IvIg | 39.3 | R | 8 mg/kg IV every 4 weeks | PSL 60 mg/day | 10 | Off |
| 10 | 33 | M | NA | GC, CYC | 16.9 | R | 8 mg/kg IV every 4 weeks | PSL 4 mg/day | 50 | Off |
| 11 | 3 | M | 9 | None | 21.9 | P | 10 mg/kg IV every 4 weeks | PSL 1 mg/kg/day, CYC | 7 | Tapered |
ADA, adalimumab; ANA, anakinra; AZA, azathioprine; CRP, C reactive protein; CyA, cyclosporine A; CYC, cyclophosphamide; ETN, etanercept; GC, glucocorticoid; IFX, infliximab; IV, intravenous; IvIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MTX, methotrexate; NA, not assessed; P, primary induction; PSL, prednisolone; R, refractory/relapsing; RTX, rituximab; SC, subcutaneous; TAC, tacrolimus; TCZ, tocilizumab.